|Lushun’s team, director of Oncology Department of affiliated Chest Hospital, found a new program of multi-line therapy for advanced non-small cell lun|
Recently, the European Journal of Clinical Oncology (ESMO) Annal of Oncology published in the 28th volume in 2017 a study titled Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (EastAsia S-1 Trial in Lung Cancer)(IF: 11.85), the lasted results by Lu Shun,director of Oncology Department of affiliated Chest Hospital, and Japan‘s National Cancer Center. Director Lu Shun is the co-author of the paper.
Japan’s National Cancer Center is a comprehensive center that integrates cancer hospitals, cancer prevention and research, aiming at cancer prevention, early detection and early treatment, which has been the most authoritative cancer treatment institution in Japan. Since 2010, Oncology Department ofChest Hospital and Japan‘s National Cancer Center have worked together to carry out clinical trials of new drugs for lung cancer. Professor Lu Shun and Professor Nokihara, director of the National Cancer Centeralso have long-term exchanges and cooperationin the area ofnew drugs for lung cancer.
The cooperative research targets at multi-line drug treatmentfor advanced non-small cell lung cancer. Tegafur is an oral anticancer agent used to treat locallyunresectable advanced or metastatic gastric cancer. Docetaxel is the current standard guideline for the treatment of advanced non-small cell lung cancer that previously failed by platinum-based chemotherapy. A total of 1154 patients were enrolled in this Phase III clinical trial, with 577 patients in the Tegafur (S1) and 577 in Docetaxel groups. The overall survival (OS) was the primary end point of the study, with total survival was respectively 12. 75 months and 12. 52 months, the progression-free survival (PFS) oftwo groups were 2.86 months and 2.89 months, which was no significant difference between the two groups in overall survival and disease-free survival. In terms of hematologic toxicity, Tegafur (S1) group was significantly lower than docetaxel group. This study establishesthe therapeutic status of Tegafur(S1) in advanced non-small cell lung cancer in the patients that have previously failed in platinum-containing chemotherapy and is expected to change the current clinical practice in this area with significant clinical implications.